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Introduction
Lung cancer is the most common cause of mortality among 
malignant tumors. With the application of lung cancer 
CT screening and advancement of treatment methods, 
the 5-year survival rate has increased from 10–20% to 
15–30% (1). Lung adenocarcinoma is the most common 
subtype of lung cancer, accounting for 40% (2). The core 
mechanism of carcinogenesis of lung adenocarcinoma is 
the somatic mutation of epidermal growth factor receptor 
(EGFR) that leads to persistent activation of EGFR tyrosine 
kinase domain in tumor tissue. Structural changes of the 
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mutation status in lung adenocarcinoma patients based on CT images, and to distinguish exon-19 deletion 
and exon-21 L858R mutation.
Methods: Two hundred sixty-three patients who underwent pre-surgical contrast-enhanced CT and 
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sampling.
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EGFR gene due to activating mutations are associated with 
the proliferation of adenocarcinoma cells. The therapeutic 
effect of tyrosine kinase inhibitors (TKIs) depends on the 
mutation type of the EGFR gene (3,4). Tumor response 
percentage of patients with activating mutant EGFR is 68% 
and the progression-free survival time in these patients is 
12.1 months compared with only 11% and 3.4 months in 
patients with wild type EGFR (5,6). The guideline from 
the College of American Pathologists, the International 
Association for the Study of Lung Cancer, and the 
Association for Molecular Pathology recommends routine 
testing for EGFR mutations to guide molecular targeted 
therapy in adenocarcinoma patients (7). 
EGFR mutation sites mostly locate in exons 18, 19, 20, 
and/or 21. The two most common activating mutations are 
exon-19 deletion (Del19) and exon-21 mutation (L858R) 
(8,9). Patients who have tumors harboring one of these 
two mutations exhibit a greater objective response rate to 
afatinib, erlotinib, and gefitinib (10). There is differential 
prognosis based on EGFR mutation: the overall survival 
time for patients with exon-19 and -21 mutations with 
targeted therapy was found to be 41 to 44 months, longer 
than those with exon-18 mutation (19 months) (11). 
Therefore, detection of specific EGFR mutations may be 
of interest in guiding the application of targeted therapy in 
lung adenocarcinoma patients.
The detection of EGFR mutation status relies on 
gene sequencing or amplification refractory mutation 
systems. These detection techniques require invasive 
sampling methods such as surgical excision or tissue 
biopsy (12), associated with costs and patient discomfort. 
More importantly, the intra-tumor heterogeneity leads to 
heterogenous biopsy sampling results. The implementation 
of these molecular tests is still moderate to poor. A 
non-invasive approach would be helpful to screen for 
EGFR mutation to guide further treatment before the 
clinical intervention. Because imaging phenotype seems 
to reflect the genotype of lung cancer (13,14), imaging 
morphology, features, and patterns, such as texture and 
intensity distribution are often used to derive information 
regarding diagnosis, tumor heterogeneity, and prognosis. In 
comparison with a traditional visual inspection, radiomics 
transforms medical images into minable data to develop 
models to guide clinical decision (15,16). Zhou et al. found 
no difference in CT morphology in 346 patients with 
and without EGFR mutation (17). Rios Velazquez et al. 
analyzed 763 adenocarcinoma cases and observed an AUC 
of 0.69 to distinguish mutant EGFR based on radiological 
features (18). However, there have been improved results 
on the association between CT radiomic features and 
EGFR mutation. Yip et al. revealed that radiomic features 
could classify the mutation status of EGFR (19). To our 
knowledge, no study has comprehensively investigated 
whether the different activating EGFR mutations can 
be estimated from imaging features. We performed a 
comprehensive CT-derived radiomics analysis on lung 
adenocarcinoma patients to classify the presence of the 
EGFR mutation status, and whether we are able to classify 
exon-19 deletion and exon-21 L858R mutation.
Methods
Study population
From July 2017 to December 2018, an exhaustive search 
in the electronic health records was performed for lung 
cancer patients who had molecular testing for EGFR 
mutation in our hospital. The inclusion criteria were: (I) 
tumor sample tissue obtained by surgery; (II) pathologically 
diagnosed adenocarcinoma based on hematoxylin-eosin and 
immunohistochemistry staining; (III) pre-surgery thin-slice 
(<1 mm) contrast-enhanced CT scan; (IV) time interval 
less than 2 months between CT scan and surgery. Patients 
were excluded if the tumor edge was indistinguishable 
with the naked eyes, and thus impossible to accurately 
segment on the CT images, caused by factors such as 
unclear demarcation between the tumor and surrounding 
consolidation or pleural effusion, etc. This retrospective 
study was approved by the Institutional Review Committee 
and waived the requirement for informed consent. 
The collected data were patient characteristics, smoking 
status including non-smoker or smoker (former or current), 
histological subtype of adenocarcinoma and molecular 
outcome. The study flow diagram is shown in Figure 1.
CT acquisition
CT examinations were performed on three modern 
CT systems (Somatom Force, Siemens Healthineers; 
Revolution and HD750, GE Healthcare). All included 
patients underwent contrast-enhanced chest CT scanning 
after injection of 60–80 mL contrast-media (Iopamiro 
300, Bracco) into the antecubital vein at 3 mL/sec. The 
reconstructed slice thickness was 0.6 or 0.625 mm. The 
detailed acquisition protocol and reconstruction parameters 
are listed in Table S1.
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Histologic evaluation and molecular testing 
T h e  c r i t e r i a  f o r  t h e  h i s t o l o g i c a l  d e f i n i t i o n  o f 
adenocarcinoma were according to the 2015 World Health 
Organization classification of lung cancer (20). Testing 
for EGFR mutations including exon expression of 18, 19, 
20, and 21 was performed by using a human EGFR gene 
mutation detection kit (Aide Biomedical Technology). 
Tumor segmentation and radiomic feature extraction
We used a radiomics analysis package (Radiomics 1.0.9a, 
Siemens Healthineers) on a research platform (SyngoVia 
VB10b, Research Frontier, Siemens Healthineers) to 
three-dimensionally segment the tumor on CT images as 
a volume of interest and extracted radiomic features (21). 
Two radiologists with experiences of at least five years in 
diagnostic chest CT semi-automatically segmented these 
tumors, by finding the lesion and click on it. Then the 
software automatically segmented the lesion.
A total of 1,672 features were extracted from each tumor 
(https://cdn.amegroups.cn/static/application/8373764accc
56018fb4582edf66e4fe4/tlcr-20-122-1.pdf). The extracted 
computational features were classified into original features, 
filtered (9 types) and wavelet transformed (8 types). The 
composition and classification of features were listed in 
Figure S1. The algorithmic principles are explained in the 
Supplementary File.
Feature selection
Features with a consistent correlation coefficient (CCC) 
greater than 0.70 (22) were selected for further analysis. 
Subsequently, these candidate features were characterized 
by the minimum redundancy maximum relevance (mRMR) 
algorithm, which allows for further feature selection by 
maximizing the correlation between features and label while 
minimizing the interaction information among features (23). 
All candidate radiomic features were ranked according 
to their explanatory power with regards to the presence 
of EGFR mutation. The most relevant features were 
additionally selected and clustered. The thresholds of 
significance and effect size were set to 0.05 and 0.1 for 
feature relevance, respectively. All features satisfying 
(I) Tumor segmentation 















1578 Radiomics features 
(III) Feature Selection
mRMR Algorithm
(IV) Logistic Regression 
Machine Learning
Figure 1 The study workflow diagram. (I) Tumor segmentation: the tumor was three-dimensionally semi-automatically segmented in chest 
CT images. (II) Feature extraction: 1,672 radiomic features were automatically extracted from the segmented tumor volume. (III) Feature 
selection: radiomic features were selected using the minimum redundancy maximum relevance algorithm. (IV) Logistic regression: models 
were trained and tested to determine their classification performance
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these relevance criteria were considered for subsequent 
decorrelation mRMR procedure. In this second part of the 
mRMR algorithm process, redundant features are removed. 
For decorrelation, classic mRMR was chosen in this study. 
The maximum number of features was defined as 10 and 
a fast mRMR algorithm was applied to select the proper 
number of features.
Model establishment and validation
The enrolled patients were randomly divided into training 
(80%) and test (20%) cohort for model establishment 
and validation, respectively. Five-fold cross-validation 
was performed for the data in the training cohort, to 
make sure that the stability of the established models was 
sufficient. A logistic regression algorithm was used as a 
machine learning-based classification model built with 
the features selected from the univariate statistics on the 
training cohort. Logistic regression, a traditional method in 
radiomic research, has the advantages of understandability 
and interpretability, and can incorporate both discrete and 
continuous variables (24,25).
Six logistic regression models were established 
by Radiomics software (Radiomics 1.0.9a, Siemens 
Healthineer). Three logistic regression models based on 
radiomic features were built to detect EGFR mutation, 
and to identify exon-19 deletion and exon-21 mutations, 
respectively (Model EGFR_A, Exon19A, and Exon21A). 
In addition, three multivariate logistic regression models 
were generated based on radiomic features combined with 
clinical factors (age, gender, and smoking history) (Model 
EGFR_B, Exon19B, and Exon21B). The whole training 
cohort was used to establish each model.
The most relevant model was determined by the best 
subset forward selection method. This method starts 
with an empty model and adds in first 10 features one 
by one. In each forward step, the one feature that gives 
the best improvement to the model is added. The most 
relevant model was finally selected by the model selection 
criterion. For each model, the most relevant feature 
subset was chosen by Akaike information criterion (AIC) 
and Bayesian information criterion (BIC). When fitting 
model, it is possible to lead to overfitting if increasing the 
likelihood by adding parameters, AIC and BIC are designed 
to handle this problem by introducing a penalty term for 
the number of parameters in the model. This penalty term 
is smaller in AIC than in BIC. 95% confidence level was 
reported when assessing the best subset’s model. 
Statistics
The normality of data was assessed by the Kolmogorov-
Smirnov test. An independent-sample t-test or Mann-
Whitney U test was used for continuous variables and chi-
square or Fisher’s exact test was applied for comparing 
the categorical variables. Two observers independently 
evaluated 50 randomly selected patients to access inter-
observer agreement of feature extraction expressed as an 
intraclass correlation coefficient (ICC). High ICC indicates 
high inter-observer agreement. The created logistic 
regression models were used to evaluate the classification 
of EGFR mutation in the independent test cohort. The 
model performance was assessed by using receiver operating 
characteristic (ROC) curve and area under the ROC 
curve (AUC), sensitivity, specificity, and confusion matrix. 
Pairwise comparisons were performed among AUCs by 
DeLong’s test (26). The model validation and statistical 
analysis part were performed by two software packages 
(Matlab R2019a, Mathworks; MedCalc 19.0.4, MedCalc 




Among 472 Chinese candidate patients, 263 (mean 
age 62.5±9.4 years) were finally included (Table 1). 
The training and test cohort consisted of 210 and 53 
patients, respectively. The inclusion flowchart is shown 
in Figure 2. The tumors of all patients were histologically 
confirmed lung adenocarcinoma, including 215 (81.7%) 
invasive adenocarcinoma, 30 (11.4%) microinvasive 
adenocarcinoma, and 18 (6.8%) other types. In terms of 
CT lesion density, 153 (58.2%) were solid, and 110 (41.8%) 
were sub-solid. With regards to molecular testing, 84 
(31.9%) of cancers were wild type, and 179 (68.1%) showed 
EGFR mutation, including 73 (27.8%) exon-19 deletion, 
and 99 (37.6%) exon-21 L858R mutation. Seven (2.7%) 
had a mutation of either exon-18 G719X, exon-20 20-INS, 
exon-20 S768I, exon-20 T790M, exon-21 L859R, exon-21 
L860R, or exon-21 L861R. Figure 3 shows the relationship 
between tumor location, age, and maximum tumor 
diameter. Figure 4 shows several representative cases.
In univariate analysis, female gender and subsolid density 
showed a significant positive correlation with EGFR 
mutation (P<0.01). EGFR exon-19 deletion associated 
with higher age (P=0.014), but was not associated with 
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Table 1 Patient characteristics
Characteristics
Training cohort (n=210) Test cohort (n=53)
EGFR mutant 
(n=141)





EGFR wild type 
(n=15)
P value
Age (mean ± SD) 61.4±9.7 63.0±8.8 0.365 63.4±7.4 68.9±10.7 0.066
Gender 0.002* 0.005*
Male 65 (45.8%) 48 (33.8%) 16 (11.3%) 13 (9.2%)
Female 76 (62.8%) 21 (17.4%) 22 (18.2%) 2 (1.7%)
Smoking status 0.067 0.090
Smoker 12 (38.7%) 12 (38.7%) 3 (9.7%) 4 (12.%9)
Non-smoker 129 (55.6%) 57 (24.6%) 35 (15.1%) 11 (4.7%)
Lesion density 0.001* 0.127
Subsolid 67 (60.9%) 19 (17.3%) 20 (18.2%) 4 (3.6%)
Solid 74 (48.4%) 50 (32.7%) 18 (11.8%) 11 (7.2%)
Maximum 3D diameter 0.304 0.556
≥3 cm 66 (51.2%) 38 (29.5%) 19 (14.7%) 6 (4.7%)
<3 cm 75 (56.0%) 31 (23.1%) 19 (14.2%) 9 (6.7%)
Lesion location 0.447 0.115
Right upper lobe 45 (51.7%) 23 (26.4%) 11 (12.6%) 8 (9.2%)
Right middle lobe 13 (65.0%) 2 (10.0%) 4 (20.0%) 1 (5.0%)
Right lower lobe 25 (55.6%) 10 (22.2%) 10 (22.2%) 0 (0%)
Left upper lobe 38 (53.5%) 21 (29.6%) 9 (12.7%) 3 (4.2%)
Left lower lobe 20 (50%) 13 (32.5%) 4 (10.5%) 3 (7.5%)
Histologic subtype 0.669 0.524
Invasive adenocarcinoma 113 (52.6%) 57 (26.5%) 33 (15.3%) 12 (5.6%)
Microinvasive 
adenocarcinoma
18 (60.0%) 6 (20.0%) 4 (13.3%) 2 (6.7%)
Other subtypes 10 (55.6%) 6 (33.3%) 1 (5.6%) 1 (5.6%)
Data are represented as mean ± standard deviation or number (percentage). P value stands for the comparison between EGFR mutant 
and wildtype. * indicates significantly correlated. Other subtypes include 6 adenocarcinomas in situ, 4 low differentiated adenocarcinomas, 
1 poor differentiated adenocarcinoma, 3 unclassified adenocarcinomas, 1 mixed invasive adenocarcinoma and sarcomatoid carcinoma, 
1 micropapillary adenocarcinoma, 1 solid adenocarcinoma with the mucus secretion, 1 mixed infiltrating mucinous and non-mucinous 
adenocarcinoma. EGFR, epidermal growth factor receptor; SD, standard deviation.
other clinical factors (P>0.05). Exon-21 mutation was more 
common in men (P=0.016) and in solid lesions (P=0.005). 
Classification of EGFR mutation status
A total of 1,672 radiomic features were extracted from 
each tumor. The ICC between two assessments for all 
extracted features was 0.937±0.063, indicating an optimal 
interobserver agreement. Summary of diagnostic metrics 
to detect EGFR mutation, exon-19 deletion, and exon-21 
L858R mutation is shown in Table 2.
To establish a multivariate logistic regression model for 
only radiomic features (Model EGFR_A), all features with 
CCC >0.7 were first selected before proceeding feature 
1217Translational Lung Cancer Research, Vol 9, No 4 August 2020
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Candidate patients (n=472) 
   Not sampled by surgery (n=57)
   Not adenocarcinoma (n=10)
Adenocarcinoma patients with molecular testing 
for EGFR mutation (n=405)
Included patients (n=263)

















   Not scanned by thin-slice contrast-enhanced CT (n=134)
   Over 2 months between CT scan and surgery (n=5)
   Unsegmentable tumor edge (n=3)  
Figure 2 The patient selection workflow of the study cohort. EGFR, epidermal growth factor receptor.

















Figure 3 The bubble chart of lung cancers about the relationship between location, age, and the maximum diameter of tumors. Each 
bubble represents the maximum three-dimensional diameter of the tumor. This figure shows the distribution of the variable size of lung 
adenocarcinomas among five pulmonary lobes.
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Figure 4 Representative CT images with tumor segmentation by the radiomics analysis platform. (I) Axial views show a lobulated lung 
tumor for image segmentation. (II) Axial view, (III) coronal view, and (IV) sagittal view showed segmented lung tumors indicated by a 
yellow overlay. (V) Three-dimensional views of the segmented tumors. (A) (I-V) A 61-year-old male non-smoker, with EGFR wild-type 
lung adenocarcinoma. CT mediastinal window showed a solid mass in the upper lobe of the left lung with lobulation sign and a maximum 
diameter of about 20 mm. (B) (I-V) A 58-year-old male smoker, with lung adenocarcinoma of EGFR exon-19 deletion. CT mediastinal 
window showed a solid mass in the upper lobe of the right lung with a maximum diameter of about 35 mm, rough margin, and lobulated 
sign. (C) (I-V) A 48-year-old female non-smoker, with lung adenocarcinoma of EGFR exon-21 L858R mutation. CT mediastinal window 
showed a solid mass in the lower lobe of the left lung with a maximum diameter of about 36 mm, burrs, and lobulation. EGFR, epidermal 
growth factor receptor.
processing. Then 172 features that were both statistically 
significantly correlated with EGFR mutation and non-
redundant were finally selected by the mRMR algorithm. 
Subsequently, Model EGFR_A was established by selecting 
the top 10 most relevant features, which were all image 
texture features (Table S2). When clinical factors were 
integrated (Model EGFR_B), the resulting top 10 features 
changed to one clinical character (gender), three first-order, 
and six texture features (Table S3). 
Adding clinical factors to the regression models 
improved the performance of the model. In the training 
cohort, the AUC increased from 0.73 (95% CI: 0.66–
0.79) to 0.78 (0.72–0.83) (DeLong’s P=0.136) with AIC 
selection criteria, and from 0.71 (0.65–0.77) to 0.77 
(0.70–0.82) (P=0.110) with BIC (Figure 5), respectively. 
In the test cohort, the AUC increased from 0.70 (0.56–
0.82) to 0.76 (0.63–0.87) (P=0.114) and significantly 
increased from 0.65 (0.51–0.78) to 0.76 (0.62–0.84) 
(P=0.011), respectively. Subsequently, the accuracy 
in the test cohort increased to 75.5% (61.7–86.2%) 
and 73.6% (59.7–84.7%) with AIC and BIC selection 
criteria, respectively (Table S4). Among these methods, 
Model EGFR_B using BIC selection criteria exhibited a 
sensitivity of 92.9% (76.5–99.1%).
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AUC Sensitivity Specificity Accuracy
EGFR No Akaike 0.73  
(0.66–0.79)








Bayesian 0.71  
(0.65–0.77)








Yes Akaike 0.78  
(0.72–0.83)








Bayesian 0.77  
(0.70–0.82)










No Akaike 0.75  
(0.69–0.81)
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Classification of EGFR exon-19 deletion and exon-21 
L858R mutation
For exon-19 deletion, 71 features were finally selected 
by mRMR and the top 10 most relevant features were all 
texture types (Table S5). Adding clinical factors changed the 
top 10 features to one clinical feature (age), three first-order, 
and six texture features (Table S6). When training Model 
Exon19, integration of clinical factors significantly improved 
AUC with AIC selection criteria (DeLong’s P=0.019) but 
not improved with BIC (P=0.835) (Figure S2). Additionally, 
in both training and test cohort of Model Exon19, the AUC 
of AIC selected models was larger than that of BIC selected 
models. The highest accuracy among the two models in 
the test cohort was 73.6% (59.7–84.7%) with AIC selection 
criteria without the integration of clinical factors (Table S7). 
Model Exon19B using AIC selection criteria exhibited a 
specificity of 86.7% (69.3–96.2%).
Regarding exon-21 L858R mutation, more features were 
selected. The top 10 most relevant features are shown in 
Tables S8 and S9. When training Model Exon21, integration 
of clinical factors did not improve AUC with AIC selection 
criteria (P=0.413), but significantly improved with BIC 
(P=0.043) (Figure S3). Using Model Exon21, the highest 
accuracy among the two models in the test cohort was 62.3% 
(47.9–75.2%) with AIC selection criteria with the integration 
of clinical factors (Table S10). Model Exon21B using AIC 
selection criteria exhibited a specificity of 70.4% (49.8–86.3%).
Discussion
In this study, we established six logistic regression models 
1220 Liu et al. 3D radiomics predicts EGFR mutations in lung adenocarcinoma
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Figure 5 Diagnostic performance of the radiomic features in training and test dataset for EGFR mutation status (Model EGFR). (A) (I) 
ROC curve in the training dataset by AIC selection criteria; (II) ROC curve by BIC selection criteria; (III) Heatmap of the top 10 most 
relevant features. The training was performed using image features without clinical factors. (B) (I) ROC curve in the training dataset by AIC 
selection criteria; (II) ROC curve by BIC selection criteria; (III) Heatmap of the top 10 most relevant features. The training was performed 
using image features and clinical factors. (C) (I) ROC curve in the test dataset using radiomic features and clinical factors by AIC selection 
criteria; (II) ROC curve using radiomic features and clinical factors by BIC selection criteria. ROC, receiver operating characteristic; AIC, 
Akaike information criterion; BIC, Bayesian information criterion. 
based on radiomic features and clinical factors to identify 
and differentiate EGFR mutations. The highest sensitivity 
among the two models to identify EGFR mutation was 
92.9%, indicating a very low false-negative rate. This 
suggests that a radiomics based model can be helpful 
to select EGFR mutation patients for further invasive 
procedures. The highest specificities among two exon-19 
deletion classifying models and among two exon-21 L858R 
mutation models were 86.7% and 70.4%, respectively, 
indicating a low false-positive rate. Our study reveals the 
possibility to screen for EGFR mutation by radiomic 
features on CT images.
In this study, a multivariate model combining radiomic 
features as well as patient characteristics improved the 
diagnostic performance to detect EGFR mutation in lung 
adenocarcinoma patients and reached an AUC of 0.78 and 
0.76 in the training and test cohort, respectively. Liu et al. 
also showed that CT imaging features of adenocarcinoma 
combined with clinical variables could better classify EGFR 
mutation status than only using clinical variables (27). 
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Yip et al. reported an AUC of 0.67 in predicting EGFR 
mutation status (19). Zhang et al. reported an AUC of 0.86 
and 0.87 for the training and validation cohort, respectively, 
based on 140 patients, including 68 adenocarcinomas, 54 
squamous cell carcinoma, and 18 others (28). Our results 
were based on 263 patients with histologically confirmed 
lung adenocarcinoma, which might be closer to a clinical 
setting, in view of the experience that the therapeutic effect 
of tyrosine kinase inhibitors is more significant in lung 
adenocarcinoma. Importantly, we found a sensitivity to 
detect EGFR mutation of 92.9%, which indicates a very 
low false-negative rate.
In addition, we found that lung cancer was located 
predominantly in the upper lobes, especially on the right 
side (Table 1), that is consistent with the prior study (29). 
One well-accepted explanation is that hazardous particles 
deposit more readily in the upper lobes because of the 
gravity and ventilation, and they may persist longer there 
due to less relative ventilation or less efficient lymphatic 
clearance (30). Another reason might be the higher 
tissue PO2 levels in the upper lobes that help with tumor 
initiation, and neovascularization.
The major strength of this study is a comprehensive 
analysis of the two most common activating EGFR 
mutations,  exon-19 deletion, and exon-21 L858R 
mutation. Rosell et al. found that the probability of 
mutation sites of EGFR gene expression was higher in 
exon-19 than in exon-21 (31). Therapeutic effects of TKIs 
in EGFR mutation-positive lung cancer patients differ due 
to specific activating EGFR mutation (32-34). To the best 
of our knowledge, only a few studies investigated imaging 
factors associated with exon expression. Li et al. showed an 
AUC of approximately 0.79 for the detection of exon-19 
deletion and exon-21 mutations using radiomics, but did 
not apply the model to an independent test cohort (35). 
Our results reveal that radiomic features have a high 
specificity to identify exon-19 deletion and exon-21 L858R 
mutation. 
3D segmentation algorithm was applied to extract a large 
number of candidate radiomic features for establishing 
the predicting model. Most radiomics-related studies only 
extracted relatively few features for analysis (35-38). In our 
study, 1,672 features covering three different categories 
and various filters and translations were extracted in the 
feature extraction stage, which provides a broad base for 
features involving in the predicting models. These features 
can maximize the potential information hidden behind the 
images, thus improving the capacity of established models.
Radiomics has received extensive attention in recent 
years (21,22,24). The intrinsic association between 
image features and EGFR gene expression in lung 
adenocarcinoma could be explored further by data mining 
for diagnosis, prognosis, and clinical decision-making (36). 
Zhang et al. combined clinical data and 485 radiation 
features extracted from CT images to classify EGFR 
mutation status, finally reached an accuracy of 75.6% (28). 
There are some radiomics studies on lung adenocarcinoma 
that reported similar contributing features as our study. 
For the EGFR mutation detection models, the radiomic 
features entered the model all reflect texture-related 
information. Park et al. (39) and Jiang et al. (40) included 
glszm_ZoneEntropy feature, representing the tumor 
heterogeneity in the texture pattern, in the radiomic 
models to predict the subtype and spread through air space 
in lung adenocarcinoma patients. Hong et al. (41) and Sun 
et al. (42) showed that InverseVariance was associated with 
EGFR mutation and invasion in patients with advanced 
lung adenocarcinoma. In addition, skewness, mean 
and median that belong to the first-order feature type 
contributed to the radiomic models in predicting lesion 
invasion (42), ALK mutation (43), spread through air space 
(40) and EGFR mutation (41).
There are limitations to this study. First, this evaluation 
was a retrospective study performed in a single center. 
Ideally, a multicenter prospective study would enhance 
the conclusion of this study, as well as test the effect of the 
implementation of such a radiomics-based model in clinical 
practice. Second, although we included 263 patients, 
increasing the sample size would further strengthen the 
accuracy of the algorithm model in this study. Third, one 
single algorithm was used for feature selection and building 
regression model, more algorithms could increase the 
robustness by horizontal comparison.
Conclusions
CT radiomics can sensitively identify the presence of EGFR 
mutation with a low false-negative rate, and increase the 
certainty of identification of EGFR exon-19 deletion and 
exon-21 L858R mutation in lung adenocarcinoma patients 
but the discrimination between both DNA aberrations show 
less specificity. CT radiomics may become a non-invasive 
alternative biomarker to select EGFR mutation patients for 
invasive sampling.
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Predictive features
In the six top-10 most relevant feature lists for the six models in the maintext classifying EGFR mutation and exon expression, 
glcm-Cluster Shade feature existed in all the six lists, glcm-Correlation in four models (Model EGFR_A, Model EGFR_B, 
Model Exon19A, Model Exon19B), and glcm-Inverse Variance in four models (Model EGFR_A, Model EGFR_B, Model 
Exon21A, Model Exon21B). Gray-level co-occurrence matrix (GLCM) is a statistical method of examining image texture that 
considers the spatial relationship of pixels. More details for radiomic features interpretation are shown as the following. 
Radiomic features interpretation
1. gldm-Large Dependence High Gray Level Emphasis (LDHGLE) (Model EGFR_A):










The joint distribution of large dependence is measured with higher gray-level values.

















ID (a. K. A. homogeneity 1) is another measure of image local homogeneity. If the gray level is more uniform, the 
denominator will remain at a lower level, thus produce a higher overall value.
3. glszm-Zone Entropy (ZE) (Model EGFR_A):
 2
1 1
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g sN N
i j
p i j p i j ∈
= =
= +∑∑  [3]
Here,  ϵ is an arbitrarily small positive number (≈2.2×10−16).
Uncertainty/randomness of ZE measures area size and gray distribution. The larger the value, the stronger the heterogeneity 
in the texture pattern.
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Measures the variance in dependence size in the image.
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Where μ4 is the 4th central moment.
Kurtosis is a measure of the ‘peakedness’ of the distribution of values in the image ROI. A higher kurtosis implies that the 
mass of the distribution is concentrated towards the tail (s) rather than towards the mean. A lower kurtosis implies the reverse: 
that the mass of the distribution is concentrated towards a spike near the mean value.
Related links: https://en.wikipedia.org/wiki/Kurtosis
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LRLGLRE measures the joint distribution of long run lengths with lower gray-level values.
7. gldm-Small Dependence High Gray Level Emphasis (SDHGLE) (Model Exon19_A, Model Exon19_B):
Measures the joint distribution of small dependence with higher gray-level values.
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Measures the joint distribution of large dependence with lower gray-level values.
















The correlation is between 0 (uncorrelated) and 1 (perfectly correlated), which shows the linear dependence of gray level 
values on the voxels in GLCM.
10. glcm-Informational Measure of Correlation (IMC) 2 (Model Exon19_A, Model Exon19_B):
 2( 1 )2 1 HXY HXYIMC e− −= −  [9]
IMC2 also assesses the correlation between the probability distributions of i and j (the complexity of quantifying textures). It 
should be noted that HXY1=HXY2 and HXY2−HXY≥0 represent the mutual information of the two distributions.
Therefore, the range of IMC2 = [0, 1], where 0 represents the cases of 2 independent distributions (without mutual 
information), and the maximum represents the cases of 2 complete correlation and uniform distributions [maximal mutual 
information, equal to log2 (Ng)]. In this latter case, the maximum value is then equal to 22log ( )1 Nge−− , approaching 1.








cluster prominence = i j u u p i j
=
+ − −∑∑  [10]
Cluster Prominence is a measure of skewness and asymmetry of GLCM. The larger the value is, the more asymmetric the 
average value is; the smaller the value is, the peak value appears near the average value, and the smaller the change of the 
average value is.
12. glszm-Small Area Low Gray Level Emphasis (SALGLE) (Model Exon19_A, Model Exon19_B):
 2 21 1
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SALGLE measures the proportion of the joint distribution of small size zones with lower gray-level values in the image.













Note that skipping k = 0 causes division by 0.









cluster shade = i+ j u u p i j− −∑∑
 [13]
Cluster Shade is a measure of the skewness and uniformity of the GLCM. A higher cluster shade implies greater asymmetry 
about the mean.
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Where μ3 is the 3rd central moment.
Skewness measures the asymmetry of mean distribution. According to the tail elongation and the location of the distribution 
mass concentration, the value can be positive or negative.
Related links: https://en.wikipedia.org/wiki/Skewness
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The average gray level intensity within the ROI.
17. firstorder-Median (Model EGFR B, Model Exon21_A, Model Exon21_B):
The median gray level intensity within the ROI.
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SZNN measures the variability of the volume of large and small areas in the whole image, and smaller values indicate higher 
homogeneity between the volume of large and small areas in the image. This is a standardized version of the SZN formula.
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GLV measures the variance in gray level intensities for the zones.
20. Glszm-Zone Variance (ZV) (Model Exon21_A, Model Exon21_B):
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ZV measures the variance in zone size volumes for the zones.
21. ngtdm-Contrast (Model Exon21_A, Model Exon21_B):
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Contrast is an index to measure the change of spatial intensity, but it also depends on the whole gray level dynamic range. 
When the dynamic range and spatial change rate are very high, the contrast is very high, i.e., the gray scale range is large, and 
the image between a voxel and its neighborhood changes greatly.
N.B. For fully isomorphic images, Ng, p=1, which results in dividing by 0. In this case, the arbitration value is returned to 0.
Definition of the computational medical imaging vocabulary
Radiomics: Known as computional medical imaging, involving analyzing, translating and extracting medical images into 
quantitative data to establish models for clinical decision.
Features: Quantitative variables extracted from medical images.
Training cohort: Cohort used to train a machine learning model based on radiomic features, and a set of examples applied to 
fit the parameters of the model. 
Test cohort: Cohort used to provide an unbiased assessment of the radiomic model fitting on the training cohort. The 
predicted value of the radiomic features is compared with the actual value for evaluation.
AIC: Akaike information criterion, an estimator of the relative quality of radiomic model built with training cohort. AIC 
assesses the goodness of model fitting for model selection.
BIC: Bayesian information criterion, also a criterion for model selection which is based on the likelihood function.
Figure S1 Schematic diagram of the composition and classification of 1,672 radiomic features.
Table S1 CT acquisition protocols and image reconstruction parameters
Parameter Siemens Somatom Force GE Revolution GE HD750
Acquisition mode Helical Helical Helical
Tube voltage, kV 100 120 120
Tube current, mA 130 (quality reference) 100–400 (smart mode) 100–400 (smart mode)
Collimation, mm 192×0.6 256×0.625 64×0.625
Pitch 1.2 0.984 1.39
Rotation time, ms 500 500 500
Reconstruction kernel Br44 Standard Standard
Field of view, mm 325 325 325
Slice thickness, mm 0.6 0.625 0.625
Slice increment, mm 0.6 0.625 0.625
Radiation dose, mGy ≈4.52 ≈5.20 ≈10.78
Table S2 The top 10 most relevant features (not including clinical factors) for the detection of EGFR mutation (Model EGFR_A)
Feature AUC MI R2 P
wavelet-HLH_gldm_DependenceVariance 0.665 0.041 0.077 4.16E-05
wavelet-LHL_gldm_LargeDependenceLowGrayLevelEmphasis 0.664 0.055 0.060 3.38E-04
logarithm_glcm_InverseVariance 0.627 0.035 0.047 1.52E-03
square_gldm_DependenceVariance 0.604 0.060 0.044 2.07E-03
wavelet-HLH_gldm_LargeDependenceHighGrayLevelEmphasis 0.615 0.048 0.044 2.20E-03
wavelet-HHH_glcm_Id 0.634 0.053 0.042 2.95E-03
log-sigma-0-5-mm-3D_glszm_ZoneEntropy 0.645 0.040 0.041 3.12E-03
square_glcm_Correlation 0.633 0.032 0.040 3.50E-03
original_glcm_ClusterShade 0.656 0.048 0.039 3.85E-03
wavelet-LHH_gldm_LargeDependenceHighGrayLevelEmphasis 0.585 0.030 0.037 5.16E-03
AUC, area under the receiver operating characteristic curve; MI, mutual information, represents redundancy; P value is the significance of 
the minimum redundancy maximum relevance (mRMR).
Table S3 The top 10 most relevant features (including clinical factors) for the detection of EGFR mutation (Model EGFR_B)
Feature AUC MI R2 P
wavelet-HLH_gldm_DependenceVariance 0.665 0.041 0.077 4.16E-05
custom_PatientSex 0.619 0.039 0.050 1.06E-03
logarithm_glcm_InverseVariance 0.627 0.035 0.047 1.52E-03
square_glcm_Correlation 0.633 0.032 0.040 3.50E-03
wavelet-HLL_firstorder_Kurtosis 0.599 0.037 0.031 1.07E-02
wavelet-LHL_glrlm_LongRunLowGrayLevelEmphasis 0.601 0.054 0.030 1.21E-02
wavelet-HLL_firstorder_Median 0.630 0.039 0.030 1.22E-02
original_glszm_SizeZoneNonUniformityNormalized 0.606 0.023 0.026 1.91E-02
exponential_firstorder_Skewness 0.676 0.020 0.018 4.88E-02
wavelet-LLH_glcm_ClusterShade 0.510 0.031 0.018 4.99E-02
AUC, area under the receiver operating characteristic curve; MI, mutual information, represents redundancy; P value is the significance of 
the minimum redundancy maximum relevance (mRMR).
Table S5 The top 10 most relevant features (not including clinical factors) for the detection of exon-19 deletion (Model Exon19_A) 
Feature AUC MI R2 P
wavelet-LLL_gldm_SmallDependenceHighGrayLevelEmphasis 0.608 0.029 0.044 2.26E-03
square_glcm_ClusterShade 0.600 0.063 0.040 3.58E-03
wavelet-LHL_glcm_ClusterShade 0.590 0.025 0.025 2.09E-02
square_firstorder_Skewness 0.536 0.038 0.025 2.16E-02
exponential_glcm_Correlation 0.517 0.068 0.025 2.26E-02
log-sigma-2-5-mm-3D_glcm_Imc2 0.591 0.026 0.024 2.44E-02
wavelet-LLH_glcm_ClusterProminence 0.494 0.059 0.024 2.58E-02
wavelet-LHH_firstorder_Skewness 0.575 0.030 0.020 3.82E-02
log-sigma-1-5-mm-3D_gldm_LargeDependenceLowGrayLevelEmphasis 0.597 0.018 0.020 4.20E-02
exponential_glszm_SmallAreaLowGrayLevelEmphasis 0.567 0.048 0.019 4.70E-02
AUC, area under the receiver operating characteristic curve; MI, mutual information, represents redundancy; P value is the significance of 
the minimum redundancy maximum relevance (mRMR).
Table S4 Results of the logistic regression models to detect EGFR mutation in the test cohort
Label
Predicted label
Akaike information criterion Bayesian information criterion
Radiomic model (Model 
EGFR_A)
Clinical information integrated 
mode (Model EGFR_B)
Radiomic model (Model 
EGFR_A)
Clinical information integrated 
mode (Model EGFR_B)
Mutant Wildtype Mutant Wildtype Mutant Wildtype Mutant Wildtype
Actual label 
Mutant 24 5 28 3 21 4 26 2
Wildtype 14 10 10 12 17 11 12 13
Sensitivity 82.8% (64.2–94.2%) 90.3% (74.3–98.0%) 84.0% (63.9–95.5%) 92.9% (76.5–99.1%)
Specificity 41.7% (22.1–63.4%) 54.6% (32.2–75.6%) 39.3% (21.5–59.4%) 52.0% (31.3–72.2%)
Accuracy 64.2% (49.8–76.9%) 75.5% (61.7–86.2%) 60.4% (46.0–73.6%) 73.6% (59.7–84.7%)
Table S6 The top 10 most relevant features (including clinical factors) for the detection of exon-19 deletion (Model Exon19_B)
Feature AUC MI R2 P
wavelet-LLL_gldm_SmallDependenceHighGrayLevelEmphasis 0.608 0.029 0.044 2.26E-03
square_glcm_ClusterShade 0.600 0.063 0.040 3.58E-03
wavelet-LHL_glcm_ClusterShade 0.590 0.025 0.025 2.09E-02
exponential_glcm_Correlation 0.517 0.068 0.025 2.26E-02
log-sigma-2-5-mm-3D_glcm_Imc2 0.591 0.026 0.024 2.44E-02
wavelet-LLH_glcm_ClusterProminence 0.494 0.059 0.024 2.58E-02
custom_PatientAge 0.597 0.030 0.022 3.13E-02
wavelet-LHH_firstorder_Skewness 0.575 0.030 0.020 3.82E-02
log-sigma-1-5-mm-3D_gldm_LargeDependenceLowGrayLevelEmphasis 0.597 0.018 0.020 4.20E-02
exponential_glszm_SmallAreaLowGrayLevelEmphasis 0.567 0.048 0.019 4.70E-02
AUC, area under the receiver operating characteristic curve; MI, mutual information, represents redundancy; P value is the significance of 
the minimum redundancy maximum relevance (mRMR).
Figure S2 Diagnostic performance of the radiomic features in the training and test dataset for exon-19 deletion (Model Exon19). (A) (I) 
ROC curve in the training dataset by AIC selection criteria; (II) ROC curve by BIC selection criteria; (III) Heatmap of top 10 most relevant 
features. The training was performed using image features without clinical factors. (B) (I) ROC curve in the training dataset by AIC selection 
criteria; (II) ROC curve by BIC selection criteria; (III) Heatmap of top 10 most relevant features. The training was performed using image 
features and clinical factors. (C) (I) ROC curve in the test dataset using radiomic features and clinical factors by AIC selection criteria; 
(II) ROC curve using radiomic features and clinical factors by BIC selection criteria. ROC, receiver operating characteristic; AIC, Akaike 












Table S7 Results of the logistic regression models to detect exon-19 deletion in the test cohort
Label
Predicted label
Akaike information criterion Bayesian information criterion
Radiomic model  
(Model Exon19_A)
Clinical information integrated 
mode (Model Exon19_B)
Radiomic model  
(Model Exon19_A)
Clinical information integrated  
mode (Model Exon19_B)
Mutant Wildtype Mutant Wildtype Mutant Wildtype Mutant Wildtype
Actual label
Mutant 8 8 10 13 8 13 9 16
Wildtype 6 31 4 26 6 26 5 23
Sensitivity 50.0% (24.7–75.4%) 43.5% (23.2–65.5%) 38.1% (18.1–61.6%) 36.0% (18.0–57.5%)
Specificity 83.8% (68.0–93.8%) 86.7% (69.3–96.2%) 81.3% (63.6–92.8%) 82.1% (63.1–93.9%)
Accuracy 73.6% (59.7–84.7%) 67.9% (53.7–80.1%) 64.2% (49.8–76.9%) 60.4% (46.0–73.6%)
Table S8 The top 10 most relevant features (not including clinical factors) for the detection of exon-21 L858R mutation (Model Exon21_A) 
Feature AUC MI R2 P
logarithm_glcm_InverseVariance 0.675 0.061 0.097 4.09E-06
original_firstorder_Skewness 0.654 0.06 0.068 1.33E-04
wavelet-LHL_firstorder_Mean 0.643 0.064 0.052 8.75E-04
wavelet-HLL_firstorder_Median 0.666 0.033 0.045 2.02E-03
original_glszm_SizeZoneNonUniformityNormalized 0.614 0.032 0.040 3.34E-03
logarithm_ngtdm_Contrast 0.616 0.086 0.040 3.74E-03
wavelet-HHH_firstorder_Mean 0.601 0.063 0.036 5.71E-03
wavelet-LHL_glcm_ClusterShade 0.597 0.041 0.029 1.38E-02
wavelet-HHH_glszm_GrayLevelVariance 0.591 0.052 0.025 2.10E-02
wavelet-LLL_glszm_ZoneVariance 0.570 0.058 0.020 3.84E-02
AUC, area under the receiver operating characteristic curve; MI, mutual information, represents redundancy; P value is the significance of 
the minimum redundancy maximum relevance (mRMR).
Table S9 The top 10 most relevant features (including clinical factors) for the detection of exon-21 L858R mutation (Model Exon21_B) 
Feature AUC MI R2 P
logarithm_glcm_InverseVariance 0.675 0.061 0.097 4.09E-06
original_firstorder_Skewness 0.654 0.06 0.068 1.33E-04
wavelet-HLL_firstorder_Median 0.666 0.033 0.045 2.02E-03
original_glszm_SizeZoneNonUniformityNormalized 0.614 0.032 0.040 3.34E-03
logarithm_ngtdm_Contrast 0.616 0.086 0.040 3.74E-03
wavelet-HHH_firstorder_Mean 0.601 0.063 0.036 5.71E-03
wavelet-LHL_glcm_ClusterShade 0.597 0.041 0.029 1.38E-02
wavelet-HHH_glszm_GrayLevelVariance 0.591 0.052 0.025 2.10E-02
custom_PatientSex 0.579 0.017 0.023 2.63E-02
wavelet-LLL_glszm_ZoneVariance 0.570 0.058 0.020 3.84E-02
AUC, area under the receiver operating characteristic curve; MI, mutual information, represents redundancy; P value is the significance of 
the minimum redundancy maximum relevance (mRMR).
Figure S3 Diagnostic performance of the radiomic features in training and test dataset for exon-21 L858R mutation (Model Exon21). 
(A) (I) ROC curve in the training dataset by AIC selection criteria; (II) ROC curve by BIC selection criteria; (III) Heatmap of top 10 most 
relevant features. The training was performed using image features without clinical factors. (B) (I) ROC curve in the training dataset by 
AIC selection criteria; (II) ROC curve by BIC selection criteria; (III) Heatmap of top 10 most relevant features. The training was performed 
using image features and clinical factors. (C) (I) ROC curve in the test dataset using radiomic features and clinical factors by AIC selection 
criteria; (II) ROC curve using radiomic features and clinical factors by BIC selection criteria. ROC, receiver operating characteristic; AIC, 












Table S10 Results of the logistic regression models to detect exon-21 L858R mutation in the test cohort
Label
Predicted label
Akaike information criterion Bayesian information criterion
Radiomics model  
(Model Exon21_A)
Clinical information 
integrated mode  
(Model Exon21_B)
Radiomics model  
(Model Exon21_A )
Clinical information 
integrated mode  
(Model Exon21_B)
Mutant Wildtype Mutant Wildtype Mutant Wildtype Mutant Wildtype
Actual label
Mutant 13 14 14 12 13 12 13 12
Wildtype 9 17 8 19 9 19 9 19
Sensitivity 48.2% (28.7–68.1%) 53.9% (33.4–73.4%) 52.0% (31.3–72.2%) 52.0% (31.3–72.2%)
Specificity 65.4% (44.3–82.8%) 70.4% (49.8–86.3%) 67.9% (47.7–84.1%) 67.9% (47.7–84.1%)
Accuracy 56.6% (42.3–70.2%) 62.3% (47.9–75.2%) 60.4% (46.0–73.6%) 60.4% (46.0–73.6%)
